ReviewPathogens (Basel, Switzerland)2022
Development of Novel Anti-Leishmanials: The Case for Structure-Based Approaches.
Review in Pathogens (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 25 citations in OpenAlex.
- Towards precision antileishmanial drug discovery: Integrating multi-omics, functional genomics, artificial intelligence and host-directed therapeutics.Molecular biology reports · 2026Review
- The design and synthesis of cysteine protease inhibitors containing isoxazole bearing warheads against Leishmania donovani.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Antiplasmodial potential of compounds isolated from Ziziphus mucronata and their binding to Plasmodium falciparum HGXPRT using biophysical and molecular docking studies.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Vulnerable Nucleotide Pools and Genomic Instability in Yeast Strains with Deletion of theInternational journal of molecular sciences · 2025Article
- Design and Synthesis of Benzimidazole Carboxamide Cysteine Protease Inhibitors as Promising Anti-leishmanial Agents.Current medicinal chemistry · 2025Article
- The Functional Mechanism and Structure-Activity Relationship of Antibacterial Peptides.Current topics in medicinal chemistry · 2025Review
- Evaluating theHeliyon · 2024Article
- Targeting with Structural Analogs of Natural Products the Purine Salvage Pathway inTropical medicine and infectious disease · 2024Article
- Scoping Review of Deep Learning Techniques for Diagnosis, Drug Discovery, and Vaccine Development in Leishmaniasis.Transboundary and emerging diseases · 2024Article
- TargetingFrontiers in pharmacology · 2024Article
- Kaurane-Type Diterpenoids as Potential Inhibitors of Dihydrofolate Reductase-Thymidylate Synthase in New WorldAntibiotics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The neglected tropical disease (NTD) leishmaniasis is the collective name given to a diverse group of illnesses caused by ~20 species belonging to the genus
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.